Tag: monomethyl auristatin F

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of...

Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

Highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A; Seattle Genetics) in B-cell malignancies, including diffuse large B-cell lymphoma, also known as DLBCL, and B-lineage...

A randomized phase II clinical trial of denintuzumab mafodotin, also known as SGN-CD19A (SGN-19A), in combination with the second-line salvage regimen of rituximab (Rituxan®;...